Faster Drug Approvals Are Not Always Better and Can Be Worse
Abstract
Research Original Investigation Association Between Surrogate End Points and Survival in Oncology Follow-up of applications submitted to two 94. Chapman PB, Hauschild A, Robert C, et al; 100. Prasad V, Grady C. The misguided ethics of institutional review boards. JAMA. 1992;267(3): BRIM-3 Study Group. Improved survival with crossover trials. Contemp Clin Trials. 2014;37(2): 374-378. vemurafenib in melanoma with BRAF V600E 167-169. mutation. N Engl J Med. 2011;364(26):2507-2516. 90. Dwan K,...